Clarivate Integrates Dialog Solutions Products and Services into Life Sciences & Healthcare Portfolio

Today, the Dialog Solutions brand has been integrated into Clarivate. Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare.

The versatile capabilities of Dialog Solutions cater to various industries and use cases including a modular, end-to-end approach to surveillance solutions makes it a valuable asset for pharmacovigilance (PV) literature monitoring. It also supports intellectual property research, facilitates systematic reviews with comprehensive literature analysis and provides actionable insights for strategic decision-making in business intelligence.

The migration of these products and services into the Clarivate portfolio further bolster solutions that support pharmacovigilance medical literature monitoring, patent research, systematic review literature searches, MDR literature review searches, as well as competitive and business intelligence research.  Customers can leverage the combined expertise, data and technologies to make smarter and faster evidence-based decisions, boost research and clinical outcomes.

The Dialog Solutions website ( will be migrated over to, enabling these products and solutions to reach a broader global audience. In product applications, key solutions, e.g. the Dialog™ platform and Drug Safety Triager™ will   be developed and marketed under the Clarivate brand.

Clarivate continues to evolve to best serve our customers through the lens of their industry, their pain points and challenges, and their own customers. This migration serves as another milestone which further strengthens Clarivate as a leading global provider of information and insights that can transform intelligence into the answers our customers need to solve healthcare’s biggest challenges.

Clarivate strives to ensure users benefit from integrated solutions most needed to address their most urgent needs and we will continue to invest in and explore innovative technologies, including artificial intelligence and machine learning, that can support our customers’ efforts to solve healthcare’s biggest challenges across the entire drug, device and medical technology lifecycle.

To learn more about the Dialog platform, visit: here.